IL326237A - שימוש בנוגדן אנטי-אינטרלוקין-11 בהכנת תרופה לטיפול בגידולים - Google Patents

שימוש בנוגדן אנטי-אינטרלוקין-11 בהכנת תרופה לטיפול בגידולים

Info

Publication number
IL326237A
IL326237A IL326237A IL32623726A IL326237A IL 326237 A IL326237 A IL 326237A IL 326237 A IL326237 A IL 326237A IL 32623726 A IL32623726 A IL 32623726A IL 326237 A IL326237 A IL 326237A
Authority
IL
Israel
Prior art keywords
interleukin
antibody
drug
preparation
treating tumors
Prior art date
Application number
IL326237A
Other languages
English (en)
Inventor
Chang Zhang
Shasha Jiao
Rongjuan Wang
Shuang Wang
Jinchao Zhang
Original Assignee
Mabwell Shanghai Bioscience Co Ltd
Chang Zhang
Shasha Jiao
Rongjuan Wang
Shuang Wang
Jinchao Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mabwell Shanghai Bioscience Co Ltd, Chang Zhang, Shasha Jiao, Rongjuan Wang, Shuang Wang, Jinchao Zhang filed Critical Mabwell Shanghai Bioscience Co Ltd
Publication of IL326237A publication Critical patent/IL326237A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL326237A 2023-07-28 2024-07-26 שימוש בנוגדן אנטי-אינטרלוקין-11 בהכנת תרופה לטיפול בגידולים IL326237A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202310941870 2023-07-28
PCT/CN2024/107765 WO2025026206A1 (zh) 2023-07-28 2024-07-26 抗白介素-11抗体在制备肿瘤治疗药物中的应用

Publications (1)

Publication Number Publication Date
IL326237A true IL326237A (he) 2026-03-01

Family

ID=94394083

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326237A IL326237A (he) 2023-07-28 2024-07-26 שימוש בנוגדן אנטי-אינטרלוקין-11 בהכנת תרופה לטיפול בגידולים

Country Status (5)

Country Link
KR (1) KR20260057056A (he)
CN (1) CN119424631A (he)
AU (1) AU2024318593A1 (he)
IL (1) IL326237A (he)
WO (1) WO2025026206A1 (he)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003240052A1 (en) * 2002-05-24 2003-12-12 Isis Innovation Limited Il-11 derivatives and therapeutic uses thereof
CN105497893B (zh) * 2015-12-10 2019-02-01 黑龙江省科学院高技术研究院 IL-11单克隆抗体在抑制PI3K/Akt信号通路中的应用
GB201809699D0 (en) * 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
CN113651888B (zh) * 2020-08-13 2022-08-16 广东东阳光药业有限公司 Il-11的抗体及其应用
CN113980129B (zh) * 2021-01-15 2023-07-28 东大生物技术(苏州)有限公司 一组il-11单克隆抗体及其医药用途
CA3211686A1 (en) * 2021-02-26 2022-09-01 Bayer Aktiengesellschaft Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding
CN116510007A (zh) * 2022-01-29 2023-08-01 迈威(上海)生物科技股份有限公司 采用抗il-11抗体的肿瘤组合疗法
WO2023143556A1 (zh) * 2022-01-29 2023-08-03 迈威(上海)生物科技股份有限公司 一种抗白介素-11的抗体及其应用
JP2025541367A (ja) * 2022-12-18 2025-12-18 レイディアント バイオセラピューティクス インコーポレイテッド 多価および多重特異性サイトカインアンタゴニスト

Also Published As

Publication number Publication date
KR20260057056A (ko) 2026-04-27
WO2025026206A1 (zh) 2025-02-06
AU2024318593A1 (en) 2026-02-12
CN119424631A (zh) 2025-02-14

Similar Documents

Publication Publication Date Title
RU2016122654A (ru) Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
AR104812A1 (es) Combinaciones terapéuticas y métodos para tratar neoplasias
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
RU2017108173A (ru) Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1
EA201590144A1 (ru) Rspo3-связывающие агенты и их применение
RU2014144254A (ru) Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
EP3842071A4 (en) USE OF TIM-3 ANTIBODIES IN THE MANUFACTURE OF PHARMACEUTICALS FOR THE TREATMENT OF TUMORS
MX2020009842A (es) Uso de conjugados de anticuerpo-farmaco que comprenden agentes interruptores de tubulina para tratar tumor solido.
GB2627385B (en) Use of Flibanserin in preparation of drug for treating androgenic alopecia
RU2018103064A (ru) Комбинация ингибитора hdac и анти-pd-l1-антитела для лечения злокачественной опухоли
MX2011013424A (es) Metodo de tratamiento del cancer con antagonista dll4 y agente quimioterapeutico.
RU2019143403A (ru) Комбинированные терапии для лечения онкологических заболеваний
IL314346A (he) נוגדנים אנטגוניסטים של il-18bp והשימוש בהם במונותרפיה ובתרפיה משולבת בטיפול בסרטן
WO2013071056A3 (en) Combination drug therapy for the treatment of solid tumors
EA032908B1 (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
EP4445914A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMORS AND USE
EP4101464A4 (en) USE OF ANTI-PD-1 ANTIBODIES FOR THE TREATMENT OF MALIGNANT TUMORS
ZA201907754B (en) Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
Zhang et al. Autophagy prevention sensitizes AKTi-1/2-induced anti-hepatocellular carcinoma cell activity in vitro and in vivo
IL326932A (he) שימוש בנגזרת אימידאזולידינון בהכנת תרופה לטיפול בגידולים בשילוב עם רדיותרפיה, ושיטת טיפול
RU2015138576A (ru) Комбинации соединения ингибитора мек с соединением ингибитором her3/egfr и способы применения
RU2017105817A (ru) Комбинированная терапия
RU2015124954A (ru) Фармацевтические комбинации
IL314797A (he) טיפולים משולבים לטיפול בסרטן הכוללים b7-h4 נוגדן תרופתי
EP4349325A4 (en) USE OF MITOXANTRONE HYDROCHLORIDE LIPOSOME IN THE PREPARATION OF MEDICAMENTS FOR THE TREATMENT OF ADVANCED SOLID TUMORS